OrthoPediatrics Corp. Reports 17% Increase in Q1 2025 Revenue, Achieves Adjusted EBITDA Improvement

Reuters

2025/05/08

OrthoPediatrics Corp. Reports 17% Increase in Q1 2025 Revenue, Achieves Adjusted EBITDA Improvement

OrthoPediatrics Corporation, a company dedicated to pediatric orthopedics, has announced its financial results for the first quarter of 2025. The company reported a total revenue of $52.4 million, marking a 17% increase from $44.7 million in the same period last year. This growth includes a 19% increase in domestic revenue and an 11% increase in international revenue. The company achieved an adjusted EBITDA of ($0.4) million, improving from ($1.1) million in the first quarter of 2024. OrthoPediatrics also reduced its first quarter 2025 free cash flow usage by 35% compared to the prior year and anticipates achieving its first full quarter of positive free cash flow by the fourth quarter of 2025. In terms of business developments, OrthoPediatrics expanded its scoliosis portfolio with the launch of the VerteGlide™ System, which is used to treat Early Onset Scoliosis. This launch marks the company's 80th system brought to market. Furthermore, the company has increased its full year 2025 revenue guidance to a range of $236.0 million to $242.0 million, representing growth of 15% to 18% over the prior year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OrthoPediatrics Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9446670-en) on May 07, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2533966283"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2533966283\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2533966283?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-08 04:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2533966283","market":"nz","top_or_hot":-1,"title":"OrthoPediatrics Corp. Reports 17% Increase in Q1 2025 Revenue, Achieves Adjusted EBITDA Improvement","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      OrthoPediatrics Corp. Reports 17% Increase in Q1 2025 Revenue, Achieves Adjusted EBITDA Improvement\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        OrthoPediatrics Corporation, a company dedicated to pediatric orthopedics, has announced its financial results for the first quarter of 2025. The company reported a total revenue of $52.4 million, marking a 17% increase from $44.7 million in the same period last year. This growth includes a 19% increase in domestic revenue and an 11% increase in international revenue. The company achieved an adjusted EBITDA of ($0.4) million, improving from ($1.1) million in the first quarter of 2024. OrthoPediatrics also reduced its first quarter 2025 free cash flow usage by 35% compared to the prior year and anticipates achieving its first full quarter of positive free cash flow by the fourth quarter of 2025. In terms of business developments, OrthoPediatrics expanded its scoliosis portfolio with the launch of the VerteGlide™ System, which is used to treat Early Onset Scoliosis. This launch marks the company's 80th system brought to market. Furthermore, the company has increased its full year 2025 revenue guidance to a range of $236.0 million to $242.0 million, representing growth of 15% to 18% over the prior year.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OrthoPediatrics Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9446670-en) on May 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OrthoPediatrics Corp. Reports 17% Increase in Q1 2025 Revenue, Achieves Adjusted EBITDA Improvement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrthoPediatrics Corp. Reports 17% Increase in Q1 2025 Revenue, Achieves Adjusted EBITDA Improvement\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-08 04:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      OrthoPediatrics Corp. Reports 17% Increase in Q1 2025 Revenue, Achieves Adjusted EBITDA Improvement\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        OrthoPediatrics Corporation, a company dedicated to pediatric orthopedics, has announced its financial results for the first quarter of 2025. The company reported a total revenue of $52.4 million, marking a 17% increase from $44.7 million in the same period last year. This growth includes a 19% increase in domestic revenue and an 11% increase in international revenue. The company achieved an adjusted EBITDA of ($0.4) million, improving from ($1.1) million in the first quarter of 2024. OrthoPediatrics also reduced its first quarter 2025 free cash flow usage by 35% compared to the prior year and anticipates achieving its first full quarter of positive free cash flow by the fourth quarter of 2025. In terms of business developments, OrthoPediatrics expanded its scoliosis portfolio with the launch of the VerteGlide™ System, which is used to treat Early Onset Scoliosis. This launch marks the company's 80th system brought to market. Furthermore, the company has increased its full year 2025 revenue guidance to a range of $236.0 million to $242.0 million, representing growth of 15% to 18% over the prior year.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OrthoPediatrics Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9446670-en) on May 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KIDS","symbol_name":"Orthopediatrics Corp","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nNDL8mYnh9:1","article_id":"2533966283","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2533966283","pubTimestamp":1746648385,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"OrthoPediatrics Corporation, a company dedicated to pediatric orthopedics, has announced its financial results for the first quarter of 2025. The company reported a total revenue of $52.4 million, marking a 17% increase from $44.7 million in the same period last year. This growth includes a 19% increase in domestic revenue and an 11% increase in international revenue. The company achieved an adjusted EBITDA of  million, improving from  million in the first quarter of 2024. OrthoPediatrics also reduced its first quarter 2025 free cash flow usage by 35% compared to the prior year and anticipates achieving its first full quarter of positive free cash flow by the fourth quarter of 2025. In terms of business developments, OrthoPediatrics expanded its scoliosis portfolio with the launch of the VerteGlide System, which is used to treat Early Onset Scoliosis. This launch marks the company's 80th system brought to market. Furthermore, the company has increased its full year 2025 revenue guidanc","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"KIDS":"Orthopediatrics Corp","NDAQ":"纳斯达克OMX交易所"},"translate_title":"矫形儿科公司。报告2025年第一季度收入增长17%，实现调整后EBITDA改善","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"KIDS":0.9},"content_text":"OrthoPediatrics Corp. Reports 17% Increase in Q1 2025 Revenue, Achieves Adjusted EBITDA Improvement\n    \n\n        OrthoPediatrics Corporation, a company dedicated to pediatric orthopedics, has announced its financial results for the first quarter of 2025. The company reported a total revenue of $52.4 million, marking a 17% increase from $44.7 million in the same period last year. This growth includes a 19% increase in domestic revenue and an 11% increase in international revenue. The company achieved an adjusted EBITDA of ($0.4) million, improving from ($1.1) million in the first quarter of 2024. OrthoPediatrics also reduced its first quarter 2025 free cash flow usage by 35% compared to the prior year and anticipates achieving its first full quarter of positive free cash flow by the fourth quarter of 2025. In terms of business developments, OrthoPediatrics expanded its scoliosis portfolio with the launch of the VerteGlide™ System, which is used to treat Early Onset Scoliosis. This launch marks the company's 80th system brought to market. Furthermore, the company has increased its full year 2025 revenue guidance to a range of $236.0 million to $242.0 million, representing growth of 15% to 18% over the prior year.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OrthoPediatrics Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9446670-en) on May 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}